Free Trial

Theravance Biopharma (TBPH) Stock Forecast & Price Target

Theravance Biopharma logo
$13.97 +0.17 (+1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$13.96 -0.01 (-0.04%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
0
Buy
4

Based on 4 Wall Street analysts who have issued ratings for Theravance Biopharma in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 4 analysts, 2 have given a buy rating, and 2 have given a strong buy rating for TBPH.

Consensus Price Target

$21.33
52.71% Upside
According to the 4 analysts' twelve-month price targets for Theravance Biopharma, the average price target is $21.33. The highest price target for TBPH is $25.00, while the lowest price target for TBPH is $15.00. The average price target represents a forecasted upside of 52.71% from the current price of $13.97.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TBPH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Theravance Biopharma and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TBPH Analyst Ratings Over Time

TypeCurrent Forecast
8/28/24 to 8/28/25
1 Month Ago
7/29/24 to 7/29/25
3 Months Ago
5/30/24 to 5/30/25
1 Year Ago
8/29/23 to 8/28/24
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$21.33$16.60$11.33$13.75
Forecasted Upside52.71% Upside50.50% Upside22.52% Upside68.50% Upside
Consensus Rating
Strong Buy
Moderate Buy
Hold
Hold

TBPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TBPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Theravance Biopharma Stock vs. The Competition

TypeTheravance BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
3.50
2.78
2.53
Consensus RatingStrong BuyModerate BuyModerate Buy
Predicted Upside52.71% Upside15,764.30% Upside10.24% Upside
News Sentiment Rating
Neutral News

See Recent TBPH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/15/2025Zacks Research
0 of 5 stars
 UpgradeHold ➝ Strong-Buy
6/27/2025BTIG Research
2 of 5 stars
Julian Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$24.00 ➝ $25.00+123.31%
6/17/2025Jones Trading
0 of 5 stars
Debanjana Chatterjee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$24.00+123.26%
2/25/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Douglas Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00+69.30%
8/6/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/6/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$10.00 ➝ $9.00+14.50%
8/6/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$15.00 ➝ $10.00+4.28%
1/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Inline

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:21 PM ET.


TBPH Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Theravance Biopharma is $21.33, with a high forecast of $25.00 and a low forecast of $15.00.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "strong buy" TBPH shares.

According to analysts, Theravance Biopharma's stock has a predicted upside of 52.71% based on their 12-month stock forecasts.

Over the previous 90 days, Theravance Biopharma's stock had 2 upgrades by analysts.

Theravance Biopharma has been rated by research analysts at BTIG Research, Jones Trading, and Zacks Research in the past 90 days.

Analysts like Theravance Biopharma more than other "medical" companies. The consensus rating for Theravance Biopharma is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TBPH compares to other companies.


This page (NASDAQ:TBPH) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners